drugset
Drugs / Enzomenib
last change Sep 2026 re-read 9 days ago

Enzomenib

also known as DSP-5336

Small molecule

Developed for
acute lymphoblastic leukemia · acute myeloid leukemia · myelodysplastic syndrome · plasma cell myeloma
Investigated by
Sumitomo Pharma America, Inc.

Trials 2

today NCT07444268 · Ph 1 NCT04988555 · Ph 1/2
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07444268 Mar → Aug 2026 hematopoietic and lymphoid cell neoplasm Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04988555 Feb 2022 → Jun 2027 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma Sumitomo Pharma America, Inc. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2025-10-14 Sumitomo Pharma America, Inc. Results Sumitomo Pharma Presents Latest Clinical Data on Investigational Anti-Cancer Agent Enzomenib (DSP-5336) at the 2025 Annual Meeting of the Japanese Society of Hematology (JSH) sumitomo-pharma.com ↗
At JSH2025, newly extracted and analyzed data on the Japanese population were presented alongside the previously disclosed data from the overall population.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Enzomenib ClinicalTrials.gov intervention name — accepted as the source's own label NCT04988555 ↗
Known as DSP-5336 “A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)” NCT04988555 ↗
1

NCT07444268 ↗
Modality Small molecule — CHEMBL5314915 ↗
Route Oral “single oral administration” NCT07444268 ↗